Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis.

Abstract

PURPOSE OF REVIEW:

This review aims to provide a state-of-the-art perspective on the role of kidney transplantation in cases of end-stage kidney disease due to antineutrophil cytoplasmic antibody (ANCA) vasculitis. We focus on patient and graft survival in recent years, timing of transplant, impact of ANCA status, and relapse of vasculitis in the allograft.

RECENT FINDINGS:

Graft and patient outcome compare very favorably with other causes of kidney failure and several recent studies have indicated that these outcomes have improved further in recent years. Relapse of vasculitis posttransplant appears to be lower in the modern era of transplant induction. There may be an excess mortality in those transplanted less than 1 year after induction of vasculitis remission, so it is probably wise to wait for this period before proceeding with the graft. ANCA status at transplant does not appear to influence outcome.

SUMMARY:

Kidney transplantation is an excellent treatment for kidney failure due to vasculitis, although one must never lose sight of the cause of the original vasculitic kidney failure in the event of clinical deterioration of an allograft recipient, even if the diagnosis of ANCA vasculitis was many years previously.

• Authors: Sarah Moran, Mark A Little
• Journal: Current opinion in rheumatology (Curr Opin Rheumatol) Vol. 26 Issue 1 Pg. 37-41 (Jan 2014) ISSN: 1531-6963 [Electronic] United States
• PMID: 24257368 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Antineutrophil Cytoplasmic

Topics

• Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (complications)
• Antibodies, Antineutrophil Cytoplasmic (blood)
• Graft Survival
• Humans
• Kidney Failure, Chronic (etiology, surgery)
• Kidney Transplantation
• Prognosis
• Recurrence
• Time Factors
• Treatment Outcome